

Filed on behalf of: Par Pharmaceutical, Inc.

Entered: May 24, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.
Petitioner

v.

NOVARTIS AG.
Patent Owner

Case IPR2016-01059
U.S. Patent No. 5,665,772

Before PATRICK E. BAKER, *Trial Paralegal*.

PETITIONER'S UPDATED MANDATORY NOTICES

Pursuant to 37 C.F.R. § 42.8, Petitioner Par Pharmaceutical, Inc. (“Petitioner”) hereby submits the following Updated Mandatory Notices.

1. Real Parties-In-Interest (§ 42.8(b)(1)) (UNCHANGED)

Petitioner Par Pharmaceutical, Inc. (“Par”) is a real-party-in-interest for this proceeding. Out of an abundance of caution, and as a result of ongoing integration and reorganization activities, Petitioner identifies the following additional entities as real-parties-in-interest who, going forward, may have control over this proceeding: Endo International PLC; Endo DAC; Endo Management Limited; Endo Luxembourg Holding Company S.a.r.l.; Endo Luxembourg Finance Company I S.a.r.l.; Endo U.S. Inc.; Endo US Holdings Luxembourg I S.a.r.l.; Endo US Holdings Luxembourg II S.a.r.l.; Endo Health Solutions Inc.; Hawk Acquisition Ireland Limited; and Par Pharmaceutical Companies, Inc.¹ No other

¹ As a result of Endo International PLC’s acquisition of Par Pharmaceutical, Inc., Petitioner states that: Sky Growth Intermediate Holdings Corporation I, Sky Growth Intermediate Holdings Corporation II and Par Pharmaceutical Companies, Inc. were merged into and reorganized with Par Pharmaceutical Holdings, Inc., which was immediately thereafter re-named Par Pharmaceutical Companies, Inc. For clarity, the newly reorganized Par Pharmaceutical Companies, Inc. is not identical to the entity previously known by the same name.

parties exercised or could have exercised control over this petition; no other parties funded or directed this petition. *See* Office Patent Trial Practice Guide, 77 Fed. Reg. 48759-60.

2. Related Matters (§ 42.8(b)(2)) (UNCHANGED)

Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 1:14-cv-1289-RGA (D. Del.). *Novartis Pharm. Corp. et al. v. Par Pharm., Inc.*, No. 1:14-cv-1494-RGA (D. Del.). *Novartis Pharm. Corp. et al. v. Par Pharm., Inc.*, No. 1:15-cv-78-RGA (D. Del.). *Novartis Pharm. Corp. et al. v. Par Pharm., Inc.*, No. 1:15-cv-475-RGA (D. Del.). *Novartis Pharm. Corp. et al. v. Par Pharm., Inc.*, No. 1:15-cv-1050-RGA (D. Del.). Petition for *Inter Partes* Review of U.S. Patent No. 5,665,772, No. IPR2016-00084. According to USPTO records, no patent claims priority to the '772 Patent.

3. Lead and Back-Up Counsel (§ 42.8(b)(3)) (UPDATED)

Lead Counsel	Back-Up Counsel
Daniel G. Brown (Reg. No. 54,005) daniel.brown@lw.com <u>Postal & Hand-Delivery Address:</u> Latham & Watkins LLP 885 Third Avenue New York, NY 10022-4834 T: 212.906.1200; F: 212.751.4864	Robert Steinberg (Reg. No. 33,144) bob.steinberg@lw.com <u>Postal & Hand-Delivery Address:</u> Latham & Watkins LLP 355 South Grand Avenue Los Angeles, CA 90071-1560 T: 213.485.1234; F: 213.891.8763
Back-Up Counsel	

IPR2016-01059

U.S. Patent No. 5,665,772

Jonathan M. Strang (Reg. No. 61,724) jonathan.strang@lw.com <u>Postal & Hand-Delivery Address:</u> Latham & Watkins LLP 555 Eleventh Street, NW, Ste. 1000 Washington, DC 20004-1304 T: 202.637.2200; F: 202.637.2201	
---	--

4. Service Information (§ 42.8(b)(4)) (UPDATED)

Lead Counsel	Back-Up Counsel
Daniel G. Brown (Reg. No. 54,005) daniel.brown@lw.com <u>Postal & Hand-Delivery Address:</u> Latham & Watkins LLP 885 Third Avenue New York, NY 10022-4834 T: 212.906.1200; F: 212.751.4864	Robert Steinberg (Reg. No. 33,144) bob.steinberg@lw.com <u>Postal & Hand-Delivery Address:</u> Latham & Watkins LLP 355 South Grand Avenue Los Angeles, CA 90071-1560 T: 213.485.1234; F: 213.891.8763
Back-Up Counsel	
Jonathan M. Strang (Reg. No. 61,724) jonathan.strang@lw.com <u>Postal & Hand-Delivery Address:</u> Latham & Watkins LLP 555 Eleventh Street, NW, Ste. 1000 Washington, DC 20004-1304 T: 202.637.2200; F: 202.637.2201	

Dated: May 24, 2016

By: /Daniel G. Brown/

Daniel G. Brown (Reg. No. 54,005)
Latham & Watkins LLP
885 Third Avenue
New York, NY 10022-4834
212.906.1200; 212.751.4864 (Fax)

Counsel for Petitioner

IPR2016-01059
U.S. Patent No. 5,665,772

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 24th day of May, 2016, a true and correct copy of the foregoing **Petitioner's Updated Mandatory Notices** was served by Federal Express overnight delivery on Patent Owner's counsel:

Novartis Pharmaceutical Corporation
Intellectual Property Department
One Health Plaza 433/2
East Hanover, NJ 07936-1080

Nicholas N. Kallas (Reg. No. 31,530)
Raymond R. Mandra (Reg. No. 34,382)
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104-3800
ZortressAfinitorIPR@fchs.com

via FEDERAL EXPRESS overnight delivery, on May 24, 2016

By: /Daniel G. Brown/

Daniel G. Brown (Reg. No. 54,005)
Latham & Watkins LLP
885 Third Avenue
New York, NY 10022-4834
212.906.1200; 212.751.4864 (Fax)

Counsel for Petitioner